Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
2(20%)
Results Posted
50%(2 trials)
Terminated
2(20%)

Phase Distribution

Ph phase_2
2
20%
Ph not_applicable
1
10%
Ph phase_4
5
50%
Ph phase_1
2
20%

Phase Distribution

2

Early Stage

2

Mid Stage

5

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
2(20.0%)
Phase 2Efficacy & side effects
2(20.0%)
Phase 4Post-market surveillance
5(50.0%)
N/ANon-phased studies
1(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

57.1%

4 of 7 finished

Non-Completion Rate

42.9%

3 ended early

Currently Active

2

trials recruiting

Total Trials

10

all time

Status Distribution
Active(2)
Completed(4)
Terminated(3)
Other(1)

Detailed Status

Completed4
Terminated2
Recruiting1
Active, not recruiting1
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
2
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (20.0%)
Phase 22 (20.0%)
Phase 45 (50.0%)
N/A1 (10.0%)

Trials by Status

recruiting110%
active_not_recruiting110%
unknown110%
terminated220%
withdrawn110%
completed440%

Recent Activity

Clinical Trials (10)

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
10